Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Fondaparinux Compared With Heparin to Prevent Thrombotic Complications and Graft Failure in Patients Undergoing Coronary Artery Bypass Graft Surgery
Brief Summary: (i) Main Research Question(s): What is the effect of fondaparinux on coronary graft patency, heart attack, stroke, and death in patients who have undergone coronary artery bypass grafting (CABG)? To reliably answer this question requires a large randomised trial. We propose a pilot study to demonstrate the feasibility of recruiting patients into this study and of performing CT angiograms to measure graft patency at 30 days.

(ii) Why is this research important? Coronary artery bypass surgery has made a very important contribution to improving the health and survival of patients with advanced coronary artery disease but still has many problems. One in 10 patients experiences a heart attack at the time of surgery, 1 in 20 experiences a heart attack, stroke, or death during hospitalization, and 1 in 4 patients has at least 1 blocked graft within 1 year of surgery. Fondaparinux, a relatively new anticoagulant drug, has been shown to significantly reduce cardiovascular events and death in patients who have suffered a recent heart attack. Compared to established anticoagulant therapies for acute myocardial infarction, fondaparinux has been shown to be more effective with similar or lower risks of bleeding.

Fondaparinux, unlike the most commonly used anticoagulants, does not cause Heparin Induced Thrombocytopenia (HIT), a rare condition with extremely high morbidity and mortality.

This drug has never been studied in CABG patients. Our pilot study will provide key information about feasibility that will help us to design and perform a large definitive study in the future.

(iii) What is being studied? We will be looking at blood flow in bypass grafts, heart attack, stroke, venous thromboembolism and death. For safety we will be looking at bleeding, transfusion, and need for further surgery because of bleeding. We will also perform laboratory tests for HIT antibodies as their levels are prognostic for the development of HIT and are also related to morbidity and mortality. The incidence of actual HIT cases will also be recorded.


Options:
A: Arm Label: Andexanet 800mg bolus (Part I); Type: EXPERIMENTAL; Interventions: Biological: Andexanet, Other: Placebo | Arm Label: Andexanet 800mg + 960mg (Part II); Type: EXPERIMENTAL; Interventions: Biological: Andexanet, Other: Placebo | Intervention Type: BIOLOGICAL; Name: Andexanet; Assigned to Arm(s): Andexanet 800mg + 960mg (Part II), Andexanet 800mg bolus (Part I) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Andexanet 800mg + 960mg (Part II), Andexanet 800mg bolus (Part I)
B: Arm Label: Fondaparinux; Type: EXPERIMENTAL; Interventions: Drug: Fondaparinux sodium | Arm Label: unfractionated heparin; Type: OTHER; Interventions: Drug: unfractionated heparin (UFH) | Intervention Type: DRUG; Name: Fondaparinux sodium; Assigned to Arm(s): Fondaparinux | Intervention Type: DRUG; Name: unfractionated heparin (UFH); Assigned to Arm(s): unfractionated heparin
C: Intervention Type: DRUG; Name: Fondaparinux; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: SR34006 (idraparinux sodium) Injection; Assigned to Arm(s): N/A

Answer: C